vs
Prenetics Global Ltd（PRE）与Quanterix Corp（QTRX）财务数据对比。点击上方公司名可切换其他公司
Quanterix Corp的季度营收约是Prenetics Global Ltd的10.2倍（$43.9M vs $4.3M）
Prenetics是一家总部位于中国香港的健康科学企业，业务辐射美国地区，专注于癌症等疾病的早期筛查、预防与干预诊疗，致力于帮助人们更早发现健康风险，助力提升相关疾病的治疗效果，推动肿瘤等重疾的早防早治，守护公众健康。
Quanterix Corp是一家生命科学企业，研发、生产和销售超高灵敏度单分子检测诊断平台、试剂及检测服务，覆盖肿瘤、神经退行性疾病、传染病等领域，为全球科研机构、生物制药企业及临床实验室提供研究、药物开发及临床诊断相关支持。
PRE vs QTRX — 直观对比
营收规模更大
QTRX
是对方的10.2倍
$4.3M
损益表 — Q3 2023 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $4.3M | $43.9M |
| 净利润 | — | $-23.1M |
| 毛利率 | 44.9% | 45.7% |
| 营业利润率 | -396.2% | -56.4% |
| 净利率 | — | -52.7% |
| 营收同比 | — | 24.7% |
| 净利润同比 | — | -98.8% |
| 每股收益（稀释后） | — | $-0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PREQTRX
| Q4 25 | — | $43.9M | ||
| Q3 25 | — | $40.2M | ||
| Q2 25 | — | $24.5M | ||
| Q1 25 | — | $30.3M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $35.8M | ||
| Q2 24 | — | $34.4M | ||
| Q1 24 | — | $32.1M |
净利润PREQTRX
| Q4 25 | — | $-23.1M | ||
| Q3 25 | — | $-33.5M | ||
| Q2 25 | — | $-30.0M | ||
| Q1 25 | — | $-20.5M | ||
| Q4 24 | — | $-11.6M | ||
| Q3 24 | — | $-8.4M | ||
| Q2 24 | — | $-7.4M | ||
| Q1 24 | — | $-11.2M |
毛利率PREQTRX
| Q4 25 | — | 45.7% | ||
| Q3 25 | — | 42.8% | ||
| Q2 25 | — | 46.2% | ||
| Q1 25 | — | 54.1% | ||
| Q4 24 | — | 63.0% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 64.7% | ||
| Q1 24 | — | 57.8% |
营业利润率PREQTRX
| Q4 25 | — | -56.4% | ||
| Q3 25 | — | -92.8% | ||
| Q2 25 | — | -151.6% | ||
| Q1 25 | — | -86.9% | ||
| Q4 24 | — | -42.0% | ||
| Q3 24 | — | -32.8% | ||
| Q2 24 | — | -31.8% | ||
| Q1 24 | — | -47.3% |
净利率PREQTRX
| Q4 25 | — | -52.7% | ||
| Q3 25 | — | -83.3% | ||
| Q2 25 | — | -122.6% | ||
| Q1 25 | — | -67.6% | ||
| Q4 24 | — | -33.1% | ||
| Q3 24 | — | -23.3% | ||
| Q2 24 | — | -21.5% | ||
| Q1 24 | — | -34.8% |
每股收益（稀释后）PREQTRX
| Q4 25 | — | $-0.48 | ||
| Q3 25 | — | $-0.73 | ||
| Q2 25 | — | $-0.77 | ||
| Q1 25 | — | $-0.53 | ||
| Q4 24 | — | $-0.30 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | $-0.19 | ||
| Q1 24 | — | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $29.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $295.7M |
| 总资产 | — | $418.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PREQTRX
| Q4 25 | — | $29.8M | ||
| Q3 25 | — | $38.3M | ||
| Q2 25 | — | $132.9M | ||
| Q1 25 | — | $76.5M | ||
| Q4 24 | — | $56.7M | ||
| Q3 24 | — | $29.3M | ||
| Q2 24 | — | $47.0M | ||
| Q1 24 | — | $45.3M |
股东权益PREQTRX
| Q4 25 | — | $295.7M | ||
| Q3 25 | — | $314.5M | ||
| Q2 25 | — | $292.5M | ||
| Q1 25 | — | $316.4M | ||
| Q4 24 | — | $330.0M | ||
| Q3 24 | — | $338.9M | ||
| Q2 24 | — | $340.8M | ||
| Q1 24 | — | $343.4M |
总资产PREQTRX
| Q4 25 | — | $418.8M | ||
| Q3 25 | — | $444.1M | ||
| Q2 25 | — | $375.6M | ||
| Q1 25 | — | $396.5M | ||
| Q4 24 | — | $406.5M | ||
| Q3 24 | — | $411.0M | ||
| Q2 24 | — | $415.9M | ||
| Q1 24 | — | $414.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-16.4M |
| 自由现金流经营现金流 - 资本支出 | — | $-16.5M |
| 自由现金流率自由现金流/营收 | — | -37.7% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-80.0M |
8季度趋势，按日历期对齐
经营现金流PREQTRX
| Q4 25 | — | $-16.4M | ||
| Q3 25 | — | $-41.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-13.9M | ||
| Q4 24 | — | $-4.3M | ||
| Q3 24 | — | $-5.7M | ||
| Q2 24 | — | $-5.0M | ||
| Q1 24 | — | $-20.2M |
自由现金流PREQTRX
| Q4 25 | — | $-16.5M | ||
| Q3 25 | — | $-41.9M | ||
| Q2 25 | — | $-6.4M | ||
| Q1 25 | — | $-15.1M | ||
| Q4 24 | — | $-4.7M | ||
| Q3 24 | — | $-6.6M | ||
| Q2 24 | — | $-6.5M | ||
| Q1 24 | — | $-20.7M |
自由现金流率PREQTRX
| Q4 25 | — | -37.7% | ||
| Q3 25 | — | -104.2% | ||
| Q2 25 | — | -26.3% | ||
| Q1 25 | — | -49.9% | ||
| Q4 24 | — | -13.4% | ||
| Q3 24 | — | -18.4% | ||
| Q2 24 | — | -19.1% | ||
| Q1 24 | — | -64.5% |
资本支出强度PREQTRX
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | 1.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRE
暂无分部数据
QTRX
| Products | $29.2M | 67% |
| Consumable And Other Products | $12.7M | 29% |
| Service Type Warranties | $1.7M | 4% |
